Clinicopathological Features Predict Outcomes in Patients With Radioiodine‐Refractory Differentiated Thyroid Cancer Treated With Sorafenib: A Real‐World Study

Oncologist - United States
doi 10.1634/theoncologist.2019-0633
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy